RxDoctor Payments Data

David Trusel, PA

Physician Assistant · Westfield, NYNPI 1053507392

Payments from drug & device makers

$850in general payments, 2019–2025

Across 21 payments — averaging $40.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$233
  • AstraZeneca$186
  • Novo Nordisk$142
  • GSK$132
  • Edwards Lifesciences$121
  • Lilly USA, LLC$22
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$850100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$850 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$38,390
Medicare patients
149
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$86,535
OzempicSemaglutide31$59,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$36,516
XareltoRivaroxaban32$28,322
FarxigaDapagliflozin Propanediol27$22,652
Breo ElliptaFluticasone/Vilanterol31$16,149
Spiriva RespimatTiotropium Bromide13$6,666
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$6,439
Albuterol Sulfate HfaAlbuterol Sulfate125$4,249
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,023
Atorvastatin Calcium331$2,941
DilantinPhenytoin Sodium Extended12$2,595
Nano 2nd Gen Pen NeedlePen Needle, Diabetic21$1,965
Lisinopril268$1,933
Omeprazole126$1,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$142$59,65731 claims
GSKTrelegy Ellipta, Breo Ellipta$132$52,66576 claims
AstraZenecaFarxiga$186$22,65227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Westfield

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →